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Background: High circulating luteinizing hormone (LH) level is a typical biochemical feature of polycystic ovary
syndrome (PCOS) whose pathophysiology is still unclear. Certain mutations of LH and LH receptor (LHR) may lead
to changes in bioactivity of these hormones. The aim of this study was determine the role of the LH and LHR
polymorphisms in the pathogenesis of PCOS using a genetic approach.
Methods: 315 PCOS women and 212 controls were screened for the gene variants of LH G1052A and LHR
rs61996318 polymorphisms by polymerase chain reaction– restriction fragment length polymorphism (PCR-RFLP).
Results: PCOS patients had significantly more A allele frequency of LH G1052A mutations than controls (p = 0.001).
Within PCOS group, carriers of LH 1052A allele had lower LH (p = 0.05) and higher fasting glucose levels (p = 0.04).
No subjects were identified with LHR rs61996318 polymorphisms. A new LHR single nucleotide polymorphism (SNP)
was found without clear association with PCOS.
Conclusions: Results suggested LH G1052A mutation might influence PCOS susceptibility and phenotypes.
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PCOS is one of the most common endocrine disorders
in women of reproductive age, and it affects about 1 in
15 women worldwide [1]. The syndrome is characterized
by chronic anovulation or infrequent ovulation, hyperan-
drogenism and numerous follicular cysts in enlarge
ovaries. Patients with PCOS are susceptible to infertility,
obesity and insulin resistance [1]. Despite extensive
research, the precise etiology and mechanisms of PCOS
remain largely unknown. Considerable interest in the
genetics of PCOS has increased in recent years following
increasing number of familial aggregation studies. These
studies have demonstrated genetic component of
PCOS by the increasing risk ratio of siblings of
PCOS individuals compared with that of the general
population [2,3].* Correspondence: jie.qiao@263.net
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reproduction in any medium, provided the orOne typical biochemical feature of PCOS is the high
circulating LH level which is thought to be associated
with the abnormal patterns of gonadotropin pulsatility in
pituitary [4]. LH is a member of the glycoprotein
hormone family that also includes follicle stimulating
hormone (FSH), thyroid-stimulating hormone and
human chorionic gonadotropin. These hormones are α:
β heterodimers in which the α-subunit is common to all
hormones and the β-subunit is unique and confers
biologic specificity [5,6]. The effect of LH is mediated by
LHR which is expressed in the theca cells and granulose
cells. Abnormal LH signaling is believed to play a
permissive role in augmenting ovarian androgen
production in PCOS and increasing the likelihood of
anovulation [1,7].
Studies have shown that LHβ and LHR gene mutations
may change the structure or function of the LH and
LHR, either activating or inactivating their bioactivity,
which cause anovulation, amenorrhea and polycystic
ovary in women [8–10]. There are compelling evidencesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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although the results of different populations and loci of
mutation showed inconsistencies. Two missense point
mutations in the LHβ gene (Trp 8 Arg and Ile 15 Thr)
were reported to associate with PCOS in Japan and
obese PCOS women in UK. But a study of obese PCOS
from north European found LHβ gene (Trp 8 Arg and
Ile 15 Thr) were in lower frequency [11–13]. Another
LHβ gene variant G1502A in exon 3 (Gly102Ser) was
found to be higher in Singapore Chinese women who
had menstrual disorders [14]. Yet a Korean research
found no difference of LHβ gene Gly102Ser in PCOS
patients [15]. Women with LHR mutations often show
amenorrhea and infertility [5]. Chen et al. had conducted
genome-wide association study (GWAS) of PCOS in
Han Chinese women and found strong evidence of asso-
ciations between PCOS and LHR gene loci [16]. PCOS
had lower frequency of LHR 18insLQ genotype
compared with controls (24.9 % vs 28 %) in a study
which there was about 15 % lower risk for PCOS per
minor allele copy, though the lower LHR 18insLQ
frequency was not significant after Bonferroni’s correc-
tion between PCOS and controls [17]. Given the above
evidences, we decide to study both LHβ and LHR gene
variants in PCOS patients of Chinese Han women,
intending to further elucidate the genetic mutation
mechanism of LH and LHR with PCOS.
Methods
Patients
315 Chinese Han women with PCOS and 212 controls
were recruited at Peking University Third Hospital
Reproductive Centre from January 2010 to March 2012.
This study was approved by the institutional ethics
committee of the Hospital, and written informed consent
was obtained from each subject.
PCOS was diagnosed according to the 2003 Rotterdam
criteria [18]. Two out of three of the following criteria
were met for the diagnosis: oligo-ovulation and/or
anovulation,irregular menstrual cycle ( less than eight
periods per year, or cycles that are longer than 35 days,
and amenorrhoea is absence of menstruation for more
than 3 months without pregnancy), clinical and/or
biochemical signs of hyperandrogenism (Ferriman-Gallwey
score≥ 6 or total serum testosterone> 2.8nmo/l ) and
polycystic ovaries (PCO) by transvaginal ultrasound (≥12
or more follicles in each ovary measuring 2–9 mm in
diameter, and/or increased ovarian volume, >10 ml).
Patients with the following disorders were excluded:
hyperprolactinemia, nonclassic congenital adrenal hyper-
plasia, Cushing’s syndrome, androgen secreting neoplasm
and thyroid dysfunction. The control group included age
matched women with regular menstrual cycles. They were
infertile women for tubal obstruction and/or male factor.They had no clinical or biochemical signs of hyperan-
drogenism and no polycystic ovaries. All subjects (range
from 20 to 40 years old) had not taken hormonal
therapy (including oral contraceptives) for at least
3 months prior to testing.
Hormonal and biochemical measures
We collected fasting blood samples of all subjects during
the follicular phase of a menstrual cycle (spontaneous or
bleeding after progestin withdrawal). Serum LH, FSH,
testosterone (T), androstenedione (A) and insulin
concentrations were determined by chemiluminescence
immunoassay. Glucose levels, total cholesterol (CHO)
and triglycerides (TG) were determined by oxidase
methods. High-density lipoprotein (HDL) by synthetic
polymer/detergent HDL-C assay and low-density lipopro-
tein (LDL) by surfactant LDL-C assay. Body mass index
(BMI) was calculated as body weight (kg) divided by body
height squared (m2). Waist hip ratio (WHR) was calculated
as hipline divided by waistline.
Genotyping
Genomic DNA was extracted from peripheral blood
leukocytes using the standard salting out method [19].
The purity and concentration of the isolated DNA
was measured. Primers of LHβ G1502A forward:
AGTCTGAGACCTGTGGGGTCAGCTT, reverse:
GGAGGATCCGGGTGTCAGGGCTCCA. Primers of
LHR rs61996318: forward: TGATGGTGGTGGTGAT-
GATG, reverse: GGTTTCTAGCCA GCCAGTTG. PCR
amplification was performed as Nam Keun Kim et al.
described [15]. The fragment of LHR rs61996318 amplifi-
cation is 379 bp. PCR products were analyzed by
RFLP using Enzyme Rsal and then they were given to
electrophoresis on a 2 % agarose gel stained with
ethidium bromide. In Genebank, LHR rs61996318
mutation is from G!A, and the LHR protein of corre-
sponding position changes from Gln to Lys.
DNA sequencing
The LHR PCR products (315 PCOS and 122 controls)
were sequenced in both directions using primers match-
ing intronic boundaries (primer sequences as mentioned
before). All were done by automatic genotype sequencing
instrument (ABI3730XL,BigdyeV3.1) in Peking Huada
Gene Company.
Statistical analysis
Normal distribution of all clinical parameters was analyzed
using the Kolmogorov-Smirnov test. Comparisons of
normal distribution continuous variables between groups
were independent student’s t test. When continuous
variables were not normal distribution, Mann–Whitney
U-test was used. Fisher’s exact test and chi-square test
Table 2 LHβ G1052A genotype distribution in PCOS and
control women
LHβ genotype PCOS(N= 315) Controls(N=212) P
G1052G 302(95.8 %) 212(100 %) -
G1052A 10(3.2 %) 0(0 %) 0.007
A1052A 3(1.0 %) 0(0 %) 0.27
Alleles - - -
G 614(97.5 %) 414(100 %) -
A 16(2.5 %) 0(0 %) 0.001
Fisher’s exact test; Data are presented as number (percentage). (−) = not tested.
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ical variables. All analyses were performed by SPSS
software version 18.0 (SPSS Inc. Chicago, IL, USA).
NC-pass was used to perform power calculation. Tests
of statistical significance were two sided and taken as
significant when p ≤0.05.
Results
Clinical parameters
The basal demographical, hormonal and biochemical
parameters of controls and PCOS women are summar-
ized in Table 1. The age and WHR between two groups
were similar. Similar with most studies, LH and testos-
terone levels were higher in PCOS patients compared
with that of controls, the same as BMI, LH/FSH ratio, A
and TG levels. FSH level was significantly lower in
PCOS. There were no significant difference in the levels
of fasting glucose, fasting insulin, HDL, LDL and CHO
between PCOS patients and controls (Table 1).
Variants of LHβ and LHR genes polymorphisms
In PCOS group, there are 3 LHβ A1052A homozygous
patients, 10 LHβ G1052A heterozygous patients, and
the gene variants frequencies were 1.0 % and 3.2 %
respectively. There was no one LHβ G1052A gene vari-
ant in 212 controls. The LHβ G1052A heterozygous
frequency in PCOS was significantly higher than that
in controls (p = 0.007) and A allele frequency with
PCOS patients was more than that in controls
(p = 0.001, Table 2).
There were all wild type of LHR rs61996318 SNP poly-
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Independent student’s t test and Mann–Whitney U-test; Data are described in mean
syndrome; A: serum androstenedion; CHO: total cholesterol; TG: triglycerides; HDL: Hcheck its accuracy, the PCR products of 315 PCOS and
122 controls were subjected to genetic DNA sequencing
and confirmed the same result with PCR-RFLP.
A new SNP in LHR gene
In the LHR PCR products DNA sequencing map, we
found a new SNP in LHR gene NT27762960 position
near exon 7, where there was a loss of base A, in which
the gene sequencing changes from TAGCC A GAG to
TAGCC_GAG.
In PCOS group, there were 2 homozygous of this new
SNP and in controls there were 5 (p = 0.02). But the
heterozygous frequency with PCOS was higher than that
in controls (21.3 % vs. 13.9 %, p = 0.11). There was no
significant difference of missing base frequency in the
two groups (11.3 % vs. 11.1 %, Table 3).
PCOS phenotype by different LHβ and LHR genotypes
Within the PCOS cohort, genotypes of the LHβ G1052A
mutations were not associated with general clinical signs,and control women
(N = 315) Controls(N = 212)
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± SD; BMI: body mass index; WHR: waist hip ratio; PCO: polycystic ovary
igh-density lipoprotein; LDL:low-density lipoprotein. *: P≤ 0.05.
Table 3 LHR new SNP genotype distribution in PCOS and
control women
LHR new SNP genotype PCOS(N= 315) Controls(N=122) P
wild type 246(78.1 %) 100(82.0 %) -
homozygous type 2(0.6 %) 5(4.1 %) 0.03
heterozygous type 67(21.3 %) 17(13.9 %) 0.11
Alleles - - -
A 559(88.7 %) 217(88.9 %) -
Missing 71(11.3 %) 27(11.1 %) 0.93
Chi-square test; Data are presented as number and (percentage). (−) = not tested.
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(Table 4). Carriers of the LHβ 1052A allele showed lower
LH level (p = 0.05), higher fasting glucose level (p = 0.04)
and the power calculation was 79 % and 14 % respect-
ively. Although the testosterone and androstenedione
levels were similar between two LHβ genotypes groups,
the testosterone levels were 2.35, 2.58 and 4.09 nmol/L
with three LHβ A1052A homozygous PCOS subjects
respectively (data wasn’t shown in Table 4). FSH, TG,
fasting insulin levels and LH FSH ratio were similar
between two groups.
For patients with new SNP of LHR gene in PCOS
group, the LH, fasting glucose and testosterone levels
didn’t differ between mutated type and wild type. No
association of the new SNP genotypes with BMI, WHR,
amenorrhea or PCO was observed. FSH, LH/FSH, TG
and fasting insulin levels were also similar between two
groups (Table 4).
As mentioned above, symptoms or signs of PCOS
include irregular menses (IM), clinical or biochemical
hyperandrogenism (HA) and PCO according to 2003
Rotterdam criteria. There are four possible diagnosticTable 4 Clinical and endocrine-metabolic parameters with dif
in PCOS patients
LHβ1052G/G (N= 302) LHβ1052G/A+A/A
BMI(kg/m2) 24.24 ± 3.93 22.74 ± 3.83
WHR 0.83 ± 0.07 0.81 ± 0.05
Amenorrhea,n(%) 276(91.39) 11(84.62)
PCO,n(%) 282(93.37) 11(84.62)
LH(mIU/ml) 9.23 ± 6.44 5.71 ± 4.07*
FSH(mIU/ml) 6.21 ± 1.91 5.90 ± 2.28
LH/FSH 1.52 ± 0.99 1.09 ± 1.06
Testosterone ( nmol/L) 1.80 ± 1.10 1.91 ± 1.04
A( nmol/L) 13.66 ± 5.59 13.76 ± 4.59
Fasting glucose(mmol/L) 4.92 ± 0.63 5.32 ± 1.54*
Fasting insulin(uIU/ml) 9.70 ± 6.30 13.27 ± 9.38
TG(mmol/L) 1.56 ± 1.01 1.26 ± 0.49
Independent student’s t test and Mann–Whitney U-test; Data are described in meansubcategories of PCOS i.e. IM/HA/PCO, IM/HA, HA/
PCO, and IM/PCO. We analyzed and compared the distri-
bution of LHβ G1052A genotype and LHR new SNP geno-
type according to these four subgroups of our subject pool
(Figure 1). The LHβ G1052A gene variants frequency was
9.1 % in IM/HA subgroup and 7.4 % in HA/PCO sub-
group. Both are slightly higher than that of IM/HA/PCO
subgroup and IM/PCO subgroups (3.1 % and 3.8 %). But
the difference of A allele frequency was not significant
among four subgroups (p= 0.46). The four PCOS
subgroups showed similar gene variants frequency of the
LHR new SNP. IM/HA/PCO subgroup was 23 %; IM/HA
subgroup was 13.60 %; HA/PCO was 18.5 % and IM/PCO
was 22.9 % (p= 0.74).Discussion
Until now, the relationship between LH signaling pathway
and PCOS has not been defined clearly. Besides the two-
cell-two-gonadotrophin theory, LH plays a critical role in
the folliculogenesis. During the second half of the follicular
phase, LH regulates mRNA concentrations in granulose
cells for numerous genes that function in autocrine and
paracrine signaling which can help the follicle developing
well [20,21]. LH promotes the secretion of androgens by
ovarian theca cells, which may result in follicular matur-
ation arrest [22]. LHR is over expressed in theca cells and
granulose cell from PCOS patients [23,24]. Discovery of
SNP as new markers of the human genome opened novel
ways to demonstrate genetic associations of candidate
genes to complex disorders. A number of functional SNPs
have been described in LH and LHR genes which may
affect the LH and LHR bioactivity [11,25]. In the current
study, we investigated both the genotype of LHβ G1052A
and LHR rs61996318 in Han Chinese PCOS patients. LHβferent LHβ G1052A genotype and LHR new SNP genotype
(N = 13) LHR wild type (N= 246) LHR mutated type (N=69)
24.20 ± 3.91 24.15 ± 4.03
0.83 ± 0.07 0.82 ± 0.06
223(90.65) 65(94.20)
227(92.28) 66(95.65)
8.85 ± 6.47 9.96 ± 6.06
6.19 ± 1.97 6.23 ± 1.82
1.47 ± 1.02 1.61 ± 0.88
1.79 ± 1.07 1.86 ± 1.22
13.67 ± 5.50 13.63 ± 5.78
4.93 ± 0.73 4.98 ± 0.60
12.83 ± 9.13 14.24 ± 9.88
1.55 ± 0.97 1.55 ± 1.07
± SD. P≤ 0.05 was considered statistically significant. *: P≤ 0.05.
Figure 1 Distribution of LHβ G1052A genotype (a) and LHR new SNP genotype (b) in four subgroups of PCOS. PCOS patients were
divided into four subgroups according to 2003 Rotterdam criteria (IMA/HA/PCO, IM/HA, HA/PCO and IM/PCO). There were no significant
differences of these two gene mutations among four subgroups of PCOS (LHβ G1052A genotype: p = 0.46; LHR new SNP genotype: p = 0.74).
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than that of controls (p= 0.001).Within PCOS group,
LHβ1052A gene variants showed influence on LH level
(p= 0.05) and fasting glucose level (p= 0.04). No LHR
rs61996318 mutation was found in our subjects. For the
first time, we found a new SNP in LHR gene NT27762960
where a base A was missing. To our knowledge, this is the
first study to investigate the correlations of both LHβ and
LHR genotypes in PCOS.
In our study, the frequencies of LHβ G1052A homozy-
gous and heterozygous variants were 1.0 % (3/315) and
3.2 % (10/315) respectively in PCOS. In contrast, there
was no LHβ G1052A mutation (0/212) in control group.
The frequency of A allele in PCOS was significantly
higher than controls (p = 0.001). Similar with our result
that the LHβ G1052A frequency was about 4.2 %, Ramanu-
jam et al. also reported a LHβ G1052A variant frequency of
4 % (7/176) in Singapore Chinese women with menstrual
disorders and no one A allele in the control subjects (0/
200). They speculated LHβ G1052A mutations affected go-
nadal function, and the micro heterogeneity was related to
menstrual irregularity [14]. But Kim et al. studied 108 Ko-
rean women patients with endometriosis or PCOS and
found none of them were LHβ G1052A homozygous gene
variants [15]. Ramanujam et al. didn’t find any variant ei-
ther in Malays or Indians PCOS women [26]. These results
suggested that ethnicity and environment may influence
the genetic variability in PCOS patients. Specifically, differ-
ent ethnical and regional group may express different LHβ
G1052A genotype.
LHβ G1052A mutation is a single missense mutation
in exon 3 of the LHβ gene which replaces glycine
with serine at amino acid 102 [13]. Haavisto et al. had
uncovered another LH mutation (Trp8Arg and Ile15Thr,
V-LHβ) which alters the biological function of LH with
an elevation of in vitro bioactivity compared to that ofwild type LH. Heterozygous women for the V-LHβ allele
had higher levels of serum testosterone, and estradiol
[12,27]. Within PCOS group, we found that carriers of
the LHβ 1052A allele had lower LH level (5.71 vs 9.23
mIU/ml, p = 0.05). The power calculation to LH level
between two LHβ G1052A genotypes within PCOS was
79 %. Additionally, testosterone levels of three LHβ
A1052A homozygous carriers were 2.35, 2.58 and
4.09 nmol/L (data were not shown in table) respectively.
It has been well known that LH plays an important role
in secreting testosterone. This phenomenon strongly
suggested LHβ G1052A gene variants had an effect
on LH protein and may enhance the LH bioactivity.
Lamminen et al. had found that LHβ G1052A mutation
may not affect receptor binding and bioactivity of LH
[28]. However, PCOS is a heterogeneous endocrine
disorder, which is involved in many factors, such as
genetics and environment factors. Thus, the biological
function of LHβ 1052A gene variants within PCOS
microenvironment needs to be further studied.
Carriers of the LHβ 1052A allele had higher fasting
glucose level (5.32 vs 4.92 mmol/l, p = 0.04). Higher fast-
ing glucose usually represents insulin resistance or meta-
bolic dysfunction, which is one of the most common
clinical features of PCOS. Studies have confirmed insulin
can enhance the responsiveness of theca cell and granu-
lose cell to LH in PCOS women [24]. Insulin resistance
and LH interacted with each other and increase the
severity of PCOS.
We found a new SNP in LHR gene NT27762960
position near exon 7 where base A was missing. The
amino acid sequence of LHR encoded by the exons 2–10
has been shown to confer hormone specificity and bind-
ing to the gonadotropin [29]. Homozygous or compound
heterozygous inactivating gene variants of the LHR cause
gonadal resistance to hCG and LH, and the latter event
Liu et al. Reproductive Biology and Endocrinology 2012, 10:36 Page 6 of 7
http://www.rbej.com/content/10/1/36causes feedback to pituitary to result in the rising LH
level. However, the clinical phenotypes associated with
these mutations are closely correlated with the severity
of the mutation [30]. Piersma et al. found that LHR
18insLQ mutation, Asn291Ser and Ser312Asn render the
LHR bioactivity, which resulted LHR was insensitive to
LH [25,31]. Valkenburg et al. found in Caucasian PCOS
that the LHR 18insLQ frequency was lower in PCOS
patients and about 15 % lower risk for PCOS per minor
allele copy. However, Asn291Ser and Ser312Asn were
not obviously associated with PCOS. In their study the
18insLQ homozygous carriers showed 24.1 % lower
levels of estrogen (179 vs 236pmol/l) [17]. In our study,
the missing A allele frequency was similar between
PCOS and controls (11.3 % vs. 11.1 %, p = 0.93). These
LHR new polymorphisms were in Hardy–Weinberg
equilibrium (HWE) within the PCOS population and
controls. Within PCOS group, LH level of new LHR SNP
was a little higher than wild type (9.96 vs. 8.85mIU/ml),
but the difference wasn’t significant, and the same as
levels of testosterone and androstenedione. We also
didn’t find the relationship between new LHR gene SNP
and other PCOS phenotypes like PCO, BMI, fasting
glucose, and fasting insulin levels. We didn’t find the
association between the new SNP of LHR gene with
PCOS susceptibility and phenotype. Further study in this
aspect is needed.
High LH level is a significant character of PCOS.
Although LH level was no longer as a diagnostic factor
of PCOS in 2003 Rotterdam criteria, LH level or LH
FSH ratio still acts as a diagnostic criterion of PCOS in
some Asian countries such as Japan[32]. Therefore, we
analyzed these two gene variants frequencies within four
subgroups of PCOS. The minor alleles frequencies of
LHβ G1052A genotype and LHR new SNP genotype wer-
en’t significantly different among four subgroups. This
result showed that these LHβ G1052A genotype and
LHR new SNP genotype had little relationship with
PCOS diagnosis.
Based on this study, we had some limitations, such as:
1) the number of homozygous and heterozygous with
LHβ and LHR mutation was small; 2) LHβ G1052A
mutation was not in HWE; 3) The power calculation to
fasting glucose level between two LHβ G1052A
genotypes within PCOS group was low. We thought this
phenomenon was related to the low LHβ G1052A muta-
tion frequency, which was also testified in three other
studies [14,15,26].Conclusions
In summary, the current study provides new insight
into the role of LH genetics in the pathophysiology
of PCOS. We found the minor allele frequency ofLHβ G1052A was higher with PCOS; PCOS carriers
of LHβ 1052A allele had lower LH level and high
fasting glucose level. We speculated LHβ G1052A
mutation may contribute to the pathogenesis of
PCOS. The LHR rs61996318 SNP maybe highly con-
served in Chinese Han women. We also found a new
LHR SNP for the first time in PCOS and further
study is in process to elucidate the associations
between this new LHR SNP and PCOS.
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